Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia

NCT00063297 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: R209130

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.